English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Innovent Biologics Receives CTA for its anti-PD-1 Antibody

Sep. 12, 2016

Innovent Biologics, a company based in Suzhou, China, focuses on developing high quality antibody drugs to treat human diseases including cancer, autoimmune disease and ophthalmology On September, 12, 2016 it announced that it has received clinical trial application approval from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with its investigational agent IBI308, a fully human anti-PD-1 antibody, for the treatment of advanced solid tumors.  IBI308 has some distinct features that may differentiate it from other commercially available and clinical stage anti-PD1 antibodies.